Clinical Research Directory

Inclusion Criteria: 1. Meet the diagnostic criteria of Guillain - Barre syndrome; 2. The onset is within 2 weeks; 3. Age is greater than or equal to 18 years old and less than or equal to 60 years old; 4. Hughes function classification is greater than or equal to 3; 5. The subject or his legal representative can understand the purpose of the research, show sufficient compliance with the research protocol, and sign an informed consent form. Exclusion Criteria: 1. Those who are pregnant; 2. Three months before the screening period, receive immunoadsorption therapy or intravenous immunoglobulin therapy; 3. Those who have a history of allergies in the membrane of the plasma separator; 4. Those who must use angiotensin-converting enzyme inhibitor drugs within 1 week before being included in the trial and during treatment and cannot be stopped; 5. Severe active bleeding or diffuse intravascular coagulation, patients with systemic circulatory failure that are difficult to correct with drugs; 6. Severe cardiac insufficiency, that is, those who have reached NYHA IV according to the heart failure classification standards of the New York Heart Association (NYHA); 7. There are contraindications to intravenous immunoglobulin; 8. Those with other system autoimmune diseases; 9. Diagnosis of variant GBS: such as Miller-Fisher syndrome, GBS with cranial nerve damage, sensory GBS, pan-autonomous GBS. Patients with chronic inflammatory demyelinating polyperipheral neuropathy whose condition has been significantly alleviated when visiting a doctor; 10. Subjects who have participated in any other drug or medical device clinical trials within 1 month before entering the screening period; Note: Subjects who participated in observational studies (that is, the study does not require changes or other interventions) will not be excluded; 11. Patients who cannot obtain informed consent; 12. Those who cannot receive active and comprehensive treatment.